Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06087991
Other study ID # 158724
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2023
Est. completion date October 1, 2024

Study information

Verified date October 2023
Source University of Utah
Contact Jerry Cochran
Phone 801-213-0654
Email jerry.cochran@hsc.utah.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.


Description:

Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose. The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah. This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members.


Recruitment information / eligibility

Status Recruiting
Enrollment 362
Est. completion date October 1, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: For qualitative interviews with providers, administrators, stakeholders: - Must be affiliated with Castleview Hospital as a provider, administrator or stakeholder. For the quantitative surveys: - Must be a Castleview Hospital patient who receives the BINDeR-Tx model. Exclusion Criteria: For qualitative interviews with providers, administrators, stakeholders: - Not familiar with the BINDeR-Tx model - No interaction with the BINDeR-Tx model For the quantitative surveys: - Unable to speak and read English - Subject is unable to provide contact information

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Implementation of the BINDeR-Tx service model
ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.

Locations

Country Name City State
United States University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Jerry Cochran

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient Focused: Number of patients receiving services. Will be the aggregate number of individuals who received ED-initiated buprenorphine. 24 months
Secondary Implementation and service quality: Satisfaction with projected service Qualitative interviews including clinicians, hospital staff, and community members associated with Castleview Hospital will be the investigators using the Consolidated Framework for Implementation Research (CFIR). 24 months.
Secondary Implementation and service quality: Patient satisfaction Patient satisfaction will be assessed using the Patient Satisfaction Questionnaire Short Form (PSQ-18) enrollment and 6 months post enrollment
Secondary Substance use diagnosis and treatment Using the Government Performance and Results Act (GPRA) Outcome questions on substance use within the past 30 days, other substance use disorder diagnoses and treatment in the past 30 days, and mental health diagnoses. enrollment and 6 months post enrollment
Secondary Social Connectedness Social connectedness will be measured using the GPRA questions on mutual support group attendance in the last 30 days and relationship satisfaction and support. enrollment and 6 months post enrollment
Secondary Living Conditions Living conditions will be measured using the GPRA questions on residence within the past 30 days. enrollment and 6 months post enrollment
Secondary Mental and Physical Health Problems and Treatment/Recovery Mental and physical health problems and treatment/recovery will be measured using the GPRA questions on mental health symptoms and medical care received in the past 30 days and insurance status. enrollment and 6 months post enrollment
Secondary Legal Status Legal status will be measured using the GPRA questions on incarceration in the past 30 days, charges, trial, sentencing, parole, probation, and drug court status. enrollment and 6 months post enrollment
Secondary Discharge status Discharge status will be measured using the GRPA questions on substance use diagnosis and treatment in the past 30 days. enrollment and 6 months post enrollment
Secondary Follow-up Status Follow-up status will be measured using the GPRA questions on contact and follow-up status. enrollment and 6 months post enrollment
Secondary Education, Employment, and Income Education, employment, and income will be measured using the GPRA questions on education level, employment status, living expenses and income status. enrollment and 6 months post enrollment
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04839978 - Community Trial in the Cherokee Nation N/A
Completed NCT05593341 - Opioid Education in Total Knee Arthroplasty N/A
Terminated NCT04495374 - Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy Phase 4
Terminated NCT03822962 - Pain Management Following Sinus Surgery Early Phase 1
Completed NCT03936985 - Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
Active, not recruiting NCT01740414 - Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers Phase 2
Completed NCT00499746 - The Discriminative Effects of Tramadol in Humans Phase 1/Phase 2
Completed NCT03684681 - The Navigator Trial N/A
Completed NCT04340622 - Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders N/A
Completed NCT04018664 - Oral Abuse Potential Study of Nalbuphine Phase 1
Completed NCT00699010 - Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse Phase 2
Recruiting NCT05006079 - Opioid/Benzodiazepine Polydrug Abuse: Aim 3 Phase 2
Completed NCT04710069 - Postoperative Opt-In Narcotic Treatment Study N/A
Terminated NCT03992079 - A Multimodal Enhanced Recovery Program in Anorectal Surgery N/A
Active, not recruiting NCT03570099 - Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications
Completed NCT02804152 - Program for Pain & Prescription Opioid Use in Pregnancy N/A
Active, not recruiting NCT01632982 - Mobile Psychosocial Interventions for MMT Clients N/A
Active, not recruiting NCT01136356 - A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals Phase 1/Phase 2
Not yet recruiting NCT05706311 - Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool N/A
Completed NCT03743493 - PCORnet Opioid Surveillance Study